ReviewCancers2025

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma.

Piotr Kawczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.